首页> 美国卫生研究院文献>Advanced Science >Differential Monocyte Actuation in a Three‐Organ Functional Innate Immune System‐on‐a‐Chip
【2h】

Differential Monocyte Actuation in a Three‐Organ Functional Innate Immune System‐on‐a‐Chip

机译:单芯片三器官功能先天免疫系统中的差分单核细胞驱动。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A functional, human, multiorgan, pumpless, immune system‐on‐a‐chip featuring recirculating THP‐1 immune cells with cardiomyocytes, skeletal muscle, and liver in separate compartments in a serum‐free medium is developed. This in vitro platform can emulate both a targeted immune response to tissue‐specific damage, and holistic proinflammatory immune response to proinflammatory compound exposure. The targeted response features fluorescently labeled THP‐1 monocytes selectively infiltrating into an amiodarone‐damaged cardiac module and changes in contractile force measurements without immune‐activated damage to the other organ modules. In contrast to the targeted immune response, general proinflammatory treatment of immune human‐on‐a‐chip systems with lipopolysaccharide (LPS) and interferon‐ (IFN‐ ) causes nonselective damage to cells in all three‐organ compartments. Biomarker analysis indicates upregulation of the proinflammation cytokines TNF‐ , IL‐6, IL‐10, MIP‐1, MCP‐1, and RANTES in response to LPS + IFN‐ treatment indicative of the M1 macrophage phenotype, whereas amiodarone treatment only leads to an increase in the restorative cytokine IL‐6 which is a marker for the M2 phenotype. This system can be used as an alternative to humanized animal models to determine direct immunological effects of biological therapeutics including monoclonal antibodies, vaccines, and gene therapies, and the indirect effects caused by cytokine release from target tissues in response to a drug's pharmacokinetics (PK)/pharmacodynamics (PD) profile.
机译:开发了一种功能性的,人类的,多器官的,无泵的片上免疫系统,其特征是在无血清培养基中的不同隔室中,使THP-1免疫细胞与心肌细胞,骨骼肌和肝脏一起循环。这个体外平台可以模拟针对组织特异性损伤的针对性免疫反应,以及针对促炎性化合物暴露的整体促炎免疫反应。靶向反应的特征是荧光标记的THP-1单核细胞选择性渗透到胺碘酮损坏的心脏模块中,并且收缩力测量值发生变化,而没有免疫激活对其他器官模块的损害。与针对性的免疫反应相比,使用脂多糖(LPS)和干扰素(IFN-)对免疫芯片系统的一般促炎治疗会对所有三个器官区室的细胞产生非选择性损伤。生物标志物分析表明,对LPS + IFN-处理表明M1巨噬细胞表型有反应,促炎细胞因子TNF-,IL-6,IL-10,MIP-1,MCP-1和RANTES上调,而胺碘酮治疗仅导致恢复性细胞因子IL-6的增加,IL-6是M2表型的标志。该系统可以用作人源化动物模型的替代品,以确定包括单克隆抗体,疫苗和基因疗法在内的生物疗法的直接免疫学作用,以及由靶组织释放的细胞因子响应药物的药代动力学(PK)引起的间接作用/药效学(PD)配置文件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号